Division of Biology, Indian Institute of Science Education and Research (IISER) Tirupati, Tirupati, Andhra Pradesh, India.
Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, West Bengal, India.
J Cell Biochem. 2022 May;123(5):921-934. doi: 10.1002/jcb.30235. Epub 2022 Mar 16.
Krüppel-like factor 8 (KLF8) is a transcription factor expressed abnormally in various cancer types and promotes oncogenic transformation. However, the role of KLF8 in ovarian cancer (OC) progression remains unclear. This study reports that transforming growth factor-β1 (TGF-β1)/Smad2/KLF8 axis regulates epithelial-mesenchymal transition (EMT) and contributes to OC progression. We analyzed the KLF8 expression in OC cells and tissues, wherein a significant overexpression of KLF8 was observed. Increased KLF8 expressions were correlated with higher cell proliferation, EMT, migration, and invasion and conferred poor clinical outcomes in OC patients. Overexpressed KLF8 increases F-actin polymerization and induces cytoskeleton remodeling of OC cells. Furthermore, a dissection of the molecular mechanism defined that TGF-β1 triggers KLF8 through the Smad2 pathway and regulates EMT. Pharmacological and genetic inhibition of Smad2 followed by TGF-β1 treatment failed to activate KLF8 expression and induction of EMT. Using promoter-luciferase reporter assays, we defined that upon TGF-β1 activation, phosphorylated Smad2 binds and promotes the KLF8 promoter activity, and knockdown of Smad2 inhibits KLF8 promoter activation. Together, these results demonstrate that TGF-β1 activates KLF8 expression by the Smad2 pathway, and KLF8 contributes to OC progression and may serve as a potential therapeutic strategy for treating OC patients.
Krüppel 样因子 8(KLF8)是一种在多种癌症类型中异常表达的转录因子,可促进致癌转化。然而,KLF8 在卵巢癌(OC)进展中的作用尚不清楚。本研究报告转化生长因子-β1(TGF-β1)/Smad2/KLF8 轴调节上皮间质转化(EMT)并促进 OC 进展。我们分析了 OC 细胞和组织中的 KLF8 表达,其中观察到 KLF8 的显著过表达。KLF8 表达的增加与更高的细胞增殖、EMT、迁移和侵袭相关,并赋予 OC 患者不良的临床结局。过表达的 KLF8 增加 F-肌动蛋白聚合并诱导 OC 细胞的细胞骨架重塑。此外,分子机制的剖析表明 TGF-β1 通过 Smad2 途径触发 KLF8 并调节 EMT。用 Smad2 抑制剂和 TGF-β1 处理后,Smad2 的药理学和遗传学抑制均未能激活 KLF8 的表达和 EMT 的诱导。通过启动子-荧光素酶报告基因分析,我们确定在 TGF-β1 激活后,磷酸化的 Smad2 结合并促进 KLF8 启动子活性,并且 Smad2 的敲低抑制 KLF8 启动子激活。总之,这些结果表明 TGF-β1 通过 Smad2 途径激活 KLF8 的表达,KLF8 有助于 OC 的进展,并且可能作为治疗 OC 患者的潜在治疗策略。